Business Wire

DAWEX

26.3.2020 22:54:08 CET | Business Wire | Press release

Share
COVID-19 Data Exchange to Curb the Virus’ Propagation and Limit Its Economic Impact

Under the impulsion of the World Health Organization and the European Union stressing the importance of data sharing, Dawex , the leading data exchange technology company, today announced launching a COVID-19 Data Exchange initiative. The platform will be available pro bono to a large community of companies and organizations looking to contribute to the resolution of this crisis. The technology enables the exchange of vital non-personal data to hinder COVID-19’s dissemination and restrain its economic impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005767/en/

Scientific communities, hospitals and healthcare operations, pharmaceutical organizations, retailers, transport & logistics companies, specialized equipment manufacturers and distributors, consulting organizations, technology companies and health tech startups, banks, insurance, global and regional health organizations, governmental agencies, municipalities and other public services will be able to securely and easily access, publish, and exchange multiple sources of non-personal data worldwide, therefore acquiring more capabilities to answer crisis-related complex questions, faster.

“There is an unparalleled demonstration of solidarity from many organizations to contribute to the resolution of this crisis. It was an evidence for Dawex to immediately engage its resources and technology to bring the best environment to all these organizations to exchange data in the best conditions,” says Laurent Lafaye, co-founder and co-CEO of Dawex.

Join worldwide and regional organizations in this endeavour and proactively exchange critical non-personal data to contribute to stopping the virus’ progression and its economic impact. Get involved now

By using COVID-19 Data Exchange, participants remain in full control of the data they share, decide with whom they share it, and keep track of all data flows. Only vetted participants from public and private organizations will be granted access to the COVID-19 Data Exchange to ensure confidentiality and relevance of the data exchanges.

“COVID-19 crisis is challenging the way we will use data in the future. Thousands of data providers are willing to share their sources of data, right now, for free. Without trust, fairness and use cases, this effort will be pointless. Our dedicated team of experts from Deloitte, in data management, healthcare and artificial intelligence will make the most out of this coalition and Dawex technology,” says Mathieu Colas, Senior Partner at Deloitte.

“The COVID-19 Data Exchange will facilitate and accelerate data exchanges while we are in the midst of the storm. Moreover, it brings the community together, strengthening our ability to respond to future crises and prepare for a better and stronger future,” says Fabrice Tocco, co-founder and co-CEO of Dawex.

About Dawex

Dawex, a leading data exchange technology company, allows organizations to orchestrate data circulation by sourcing and exchanging data directly, securely and in full compliance with regulations. Today 10,000 organizations from 20+ sectors rely on Dawex Data Exchange solutions to build their data exchange strategy. Created in 2015, Dawex is an international company headquartered in France, and serving customers in more than 50 countries. www.dawex.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 2615.5.2026 14:00:00 CEST | Press release

LYCRA FUSION™ Fiber for Personal Care Applications Debuts The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515514441/en/ Join The LYCRA Company and Dukane at INDEX™ 26 in Geneva, as they showcase their latest advances in ultrasonic bonding for nonwovens, including new LYCRA FUSION™ fiber for personal care that delivers superior snapback. Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrason

Vecima to Highlight Next-Generation 50G-PON, DOCSIS® 4.0 vCMTS, AI & Automation, and Monetizable Streaming at ANGA COM 202615.5.2026 13:45:00 CEST | Press release

Vecima Networks Inc. (TSX: VCM) will highlight its leadership in next-generation broadband at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS® 4.0 access, and scalable fiber solutions. Anchored by the Entra® vCMTS platform, Automation, and All-PON™ innovations, Vecima is enabling operators to automate operations, improve reliability, and accelerate the evolution to converged cable and fiber networks. Delivering on Next-Generation PON With Entra All-PON™, Vecima is enabling future-ready fiber networks with a straightforward migration path from today’s 10G technologies to 50G-PON, ensuring long-term scalability and investment protection. The new Entra EPS1650 All-PON Shelf supports 50G-PON, XGS-PON, 10G-EPON, GPON, and EPON services. As a follow-on to Vecima's industry-first demonstration of a single port supporting 50G ITU PON and 10G-EPON in a Remote OLT, the EPS1650 brings that same single-port investment-protection path to GPON and XGS-PON operators in a

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release

All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of

Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release

New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that

SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release

SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye